Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kemal Malik Insider Profile
4 Followers
Kemal Malik, Director at Acceleron Pharma, holds 5.93K shares in Cartesian Therapeutics (Ticker: RNAC), holds 0.00 shares in Acceleron Pharma (Ticker: XLRN).
Kemal Malik Acceleron Pharma (XLRN)Director
Acceleron Pharma (XLRN)
Director
Not Ranked
Kemal Malik has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Director
Roles that Kemal Malik holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Kemal Malik
Kemal Malik's Trading History
Acceleron Pharma
Nov 22, 2021
―
Uninformative Sell
―
$0.00
Cartesian Therapeutics
Jul 03, 2024
Director
Uninformative Buy
―
$103.77K
List of latest transactions for each holding click on a transaction to see Kemal Malik's performance on stock
You May Also Like
Kemal Malik insider profile FAQ
What is the percentage of profitable transactions made by Kemal Malik?
The percentage of profitable transactions made by Kemal Malik is ―.
What is the average return per transaction made by Kemal Malik?
The average return per transaction made by Kemal Malik is ―.
What stocks does Kemal Malik hold?
Kemal Malik holds: XLRN, RNAC stocks.
What was Kemal Malik’s latest transaction?
Kemal Malik latest transaction was an Uninformative Buy of ―.
What was Kemal Malik's most profitable transaction?
Kemal Malik’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Kemal Malik's role in Acceleron Pharma?
Kemal Malik's role in Acceleron Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.